242 related articles for article (PubMed ID: 19064568)
21. Evolution and dynamics of pancreatic cancer progression.
Yachida S; Iacobuzio-Donahue CA
Oncogene; 2013 Nov; 32(45):5253-60. PubMed ID: 23416985
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors.
Yachida S; White CM; Naito Y; Zhong Y; Brosnan JA; Macgregor-Das AM; Morgan RA; Saunders T; Laheru DA; Herman JM; Hruban RH; Klein AP; Jones S; Velculescu V; Wolfgang CL; Iacobuzio-Donahue CA
Clin Cancer Res; 2012 Nov; 18(22):6339-47. PubMed ID: 22991414
[TBL] [Abstract][Full Text] [Related]
23. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
[TBL] [Abstract][Full Text] [Related]
24. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
[TBL] [Abstract][Full Text] [Related]
25. The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification.
Yang Y; Ding Y; Gong Y; Zhao S; Li M; Li X; Song G; Zhai B; Liu J; Shao Y; Zhu L; Pang J; Ma Y; Ou Q; Wu X; Zhang Z
BMC Cancer; 2022 Feb; 22(1):186. PubMed ID: 35180847
[TBL] [Abstract][Full Text] [Related]
26. Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma.
Franko J; Krasinskas AM; Nikiforova MN; Zarnescu NO; Lee KK; Hughes SJ; Bartlett DL; Zeh HJ; Moser AJ
J Gastrointest Surg; 2008 Oct; 12(10):1664-72; discussion 1672-3. PubMed ID: 18677542
[TBL] [Abstract][Full Text] [Related]
27. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications.
Hu HF; Ye Z; Qin Y; Xu XW; Yu XJ; Zhuo QF; Ji SR
Acta Pharmacol Sin; 2021 Nov; 42(11):1725-1741. PubMed ID: 33574569
[TBL] [Abstract][Full Text] [Related]
28. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma.
Fukushima N; Sato N; Ueki T; Rosty C; Walter KM; Wilentz RE; Yeo CJ; Hruban RH; Goggins M
Am J Pathol; 2002 May; 160(5):1573-81. PubMed ID: 12000709
[TBL] [Abstract][Full Text] [Related]
29. Genetic and epigenetic markers in the evaluation of pancreatic masses.
Ginestà MM; Mora J; Mayor R; Farré A; Peinado MA; Busquets J; Serrano T; Capellá G; Fabregat J
J Clin Pathol; 2013 Mar; 66(3):192-7. PubMed ID: 23135349
[TBL] [Abstract][Full Text] [Related]
30. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis.
Moore PS; Orlandini S; Zamboni G; Capelli P; Rigaud G; Falconi M; Bassi C; Lemoine NR; Scarpa A
Br J Cancer; 2001 Jan; 84(2):253-62. PubMed ID: 11161385
[TBL] [Abstract][Full Text] [Related]
31. Association of HPV with genetic and epigenetic alterations in colorectal adenocarcinoma from Indian population.
Laskar RS; Talukdar FR; Choudhury JH; Singh SA; Kundu S; Dhar B; Mondal R; Ghosh SK
Tumour Biol; 2015 Jun; 36(6):4661-70. PubMed ID: 25647260
[TBL] [Abstract][Full Text] [Related]
32. Pancreatic acinar cell carcinomas with prominent ductal differentiation: Mixed acinar ductal carcinoma and mixed acinar endocrine ductal carcinoma.
Stelow EB; Shaco-Levy R; Bao F; Garcia J; Klimstra DS
Am J Surg Pathol; 2010 Apr; 34(4):510-8. PubMed ID: 20182344
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenomics update in pancreatic cancer.
Puri A; Saif MW
JOP; 2014 Mar; 15(2):114-7. PubMed ID: 24618431
[TBL] [Abstract][Full Text] [Related]
34. Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma.
Sato N; Fukushima N; Matsubayashi H; Iacobuzio-Donahue CA; Yeo CJ; Goggins M
Cancer; 2006 Jul; 107(2):251-7. PubMed ID: 16752411
[TBL] [Abstract][Full Text] [Related]
35. Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.
Hayashi H; Kohno T; Ueno H; Hiraoka N; Kondo S; Saito M; Shimada Y; Ichikawa H; Kato M; Shibata T; Morizane C; Sakamoto Y; Shimada K; Komatsu Y; Sakamoto N; Okusaka T
Pancreas; 2017 Mar; 46(3):335-340. PubMed ID: 28099251
[TBL] [Abstract][Full Text] [Related]
36. A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes.
Inagawa Y; Yamada K; Yugawa T; Ohno S; Hiraoka N; Esaki M; Shibata T; Aoki K; Saya H; Kiyono T
Carcinogenesis; 2014 Aug; 35(8):1840-6. PubMed ID: 24858378
[TBL] [Abstract][Full Text] [Related]
37. Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas : frequent alterations in the APC/beta-catenin pathway and chromosome 11p.
Abraham SC; Wu TT; Klimstra DS; Finn LS; Lee JH; Yeo CJ; Cameron JL; Hruban RH
Am J Pathol; 2001 Nov; 159(5):1619-27. PubMed ID: 11696422
[TBL] [Abstract][Full Text] [Related]
38. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression.
Masugi Y; Takamatsu M; Tanaka M; Hara K; Inoue Y; Hamada T; Suzuki T; Arita J; Hirose Y; Kawaguchi Y; Nakai Y; Oba A; Sasahira N; Shimane G; Takeda T; Tateishi K; Uemura S; Fujishiro M; Hasegawa K; Kitago M; Takahashi Y; Ushiku T; Takeuchi K; Sakamoto M;
J Pathol Clin Res; 2023 Sep; 9(5):339-353. PubMed ID: 37291757
[TBL] [Abstract][Full Text] [Related]
39. Pancreatic circulating tumor cell detection by targeted single-cell next-generation sequencing.
Yu J; Gemenetzis G; Kinny-Köster B; Habib JR; Groot VP; Teinor J; Yin L; Pu N; Hasanain A; van Oosten F; Javed AA; Weiss MJ; Burkhart RA; Burns WR; Goggins M; He J; Wolfgang CL
Cancer Lett; 2020 Nov; 493():245-253. PubMed ID: 32896616
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of promoter methylation status of tumor suppressor genes in circulating DNA of pancreatic cancer patients.
Singh N; Rashid S; Rashid S; Dash NR; Gupta S; Saraya A
J Cancer Res Clin Oncol; 2020 Apr; 146(4):897-907. PubMed ID: 32146565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
